Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 12:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 71 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hypersomnia Clear all
Completed Phase 4 Interventional Results available
View directory record Official record
Conditions
Excessive Sleepiness
Interventions
Armodafinil, Placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
9
States / cities
Burlingame, California • San Diego, California • Stanford, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced May 22, 2026, 12:04 AM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Idiopathic Hypersomnia, Excessive Daytime Sleepiness
Interventions
Pitolisant
Drug
Lead sponsor
Harmony Biosciences Management, Inc.
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
32
States / cities
Los Angeles, California • San Ramon, California • Brandon, Florida + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced May 22, 2026, 12:04 AM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Idiopathic Hypersomnia
Interventions
Open-label pitolisant, Double-blind placebo, Double-blind pitolisant
Drug
Lead sponsor
Harmony Biosciences Management, Inc.
Industry
Eligibility
18 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
58
States / cities
Peoria, Arizona • Scottsdale, Arizona • Los Angeles, California + 53 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced May 22, 2026, 12:04 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Idiopathic Hypersomnia
Interventions
ALKS 2680, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
32
States / cities
Cullman, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced May 22, 2026, 12:04 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Excessive Daytime Sleepiness, Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, Chronic Shift Work Sleep Disorder
Interventions
Armodafinil 100 to 250 mg/day
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
74
States / cities
Birmingham, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 64 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced May 22, 2026, 12:04 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
JZP-110
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
22
States / cities
Birmingham, Alabama • Oceanside, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2019 · Synced May 22, 2026, 12:04 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available
View directory record Official record
Conditions
Excessive Sleepiness, Shift-work Disorder
Interventions
Solriamfetol Oral Tablet, Placebo
Drug
Lead sponsor
Charles A. Czeisler, PhD, MD
Other
Eligibility
18 Years to 64 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced May 22, 2026, 12:04 AM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Excessive Sleepiness, Shift-work Disorder
Interventions
Solriamfetol 150 mg, Solriamfetol 300 mg, Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
38
States / cities
Cullman, Alabama • Chandler, Arizona • Tucson, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced May 22, 2026, 12:04 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Excessive Sleepiness, Parkinson Disease
Interventions
JZP-110, Placebo
Drug · Other
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
35 Years to 80 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
25
States / cities
Los Angeles, California • San Diego, California • Boulder, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2020 · Synced May 22, 2026, 12:04 AM EDT
Terminated Phase 3 Interventional Results available
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Armodafinil, Placebo
Drug · Other
Lead sponsor
Cephalon, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
68
States / cities
Birmingham, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 53 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced May 22, 2026, 12:04 AM EDT
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
Idiopathic Hypersomnia
Interventions
TAK-925, TAK-925 Placebo
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
20
States / cities
Alabaster, Alabama • Glendale, Arizona • Little Rock, Arkansas + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2023 · Synced May 22, 2026, 12:04 AM EDT
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
Myotonic Dystrophy, Type 1 (DM1), Myotonic Dystrophy
Interventions
ERX-963, Placebo
Drug
Lead sponsor
Expansion Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Palo Alto, California • Miami, Florida • Iowa City, Iowa + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced May 22, 2026, 12:04 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Idiopathic Hypersomnia
Interventions
Serdexmethylphenidate, Placebo
Drug · Other
Lead sponsor
Zevra Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
41
States / cities
Birmingham, Alabama • Daphne, Alabama • Guntersville, Alabama + 34 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced May 22, 2026, 12:04 AM EDT
Terminated Not applicable Interventional Results available
View directory record Official record
Conditions
Hypersomnia
Interventions
Transcranial Direct Current Stimulation, Sham stimulation
Device
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 24, 2021 · Synced May 22, 2026, 12:04 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia
Interventions
ORX750, Placebo
Drug
Lead sponsor
Centessa Pharmaceuticals (UK) Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
29
States / cities
Auburn, Alabama • Chandler, Arizona • Scottsdale, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced May 22, 2026, 12:04 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Narcolepsy
Interventions
Modafinil
Drug
Lead sponsor
Cephalon
Industry
Eligibility
6 Years to 16 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
68
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2012 · Synced May 22, 2026, 12:04 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Narcolepsy, Cataplexy Narcolepsy, Excessive Sleepiness
Interventions
AXS-12 (Reboxetine), Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
14
States / cities
Birmingham, Alabama • Alameda, California • Santa Ana, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced May 22, 2026, 12:04 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Narcolepsy
Interventions
JZP-110, Placebo oral tablet
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
45
States / cities
Birmingham, Alabama • Glendale, Arizona • Scottsdale, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced May 22, 2026, 12:04 AM EDT
Suspended Not applicable Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Sleep Initiation and Maintenance Disorders, Circadian Rhythm Sleep Disorders, Hypersomnia
Interventions
light exposure
Procedure
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
55 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 10, 2009 · Synced May 22, 2026, 12:04 AM EDT
Recruiting Phase 2Phase 3 Interventional
View directory record Official record
Conditions
Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia
Interventions
ALKS 2680, 4mg, ALKS 2680, 6mg, ALKS 2680, 8mg, ALKS 2680, 10mg, ALKS 2680, 14mg, ALKS 2680, 18mg
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
30
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced May 22, 2026, 12:04 AM EDT
Recruiting Phase 4 Interventional
View directory record Official record
Conditions
Idiopathic Hypersomnia
Interventions
Low Sodium Oxybate, 24-hour polysomnography, Nextsense EEG earbuds, Axivity device
Drug · Diagnostic Test · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Phoenix, Arizona • Redwood City, California • Jacksonville, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced May 22, 2026, 12:04 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Narcolepsy, Sleep Apnea, Obstructive, Sleep Apnea Syndromes, Shift-Work Sleep Disorder
Interventions
CEP-10953 (Armodafinil)
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
41
States / cities
Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced May 22, 2026, 12:04 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
JZP-110, Placebo oral tablet
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
476 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
45
States / cities
Glendale, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced May 22, 2026, 12:04 AM EDT
Enrolling by invitation No phase listed Observational
View directory record Official record
Conditions
Narcolepsy, Idiopathic Hypersomnia
Interventions
24-hour Ambulatory Blood Pressure Monitoring, Oculo-Cognitive Addition Test (OCAT)
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 28, 2025 · Synced May 22, 2026, 12:04 AM EDT